[Adaptive licensing - a threat to patient safety?]

Area of Science:

• Pharmaceutical Regulation
• Drug Development
• Public Health Policy

Background:

• The European Medicines Agency (EMA) initiated a pilot project in 2014 to explore innovative medicinal product licensing.
• Traditional licensing requires extensive evidence of effectiveness and safety, often delaying market access.

Purpose of the Study:

• To investigate the feasibility and implications of adaptive licensing pathways for pharmaceutical products.
• To assess the potential benefits and risks associated with granting market authorization based on lower-level evidence.

Main Methods:

• Exploration of gradual licensing pathways allowing initial restricted market authorization.
• Consideration of data from various sources, including less validated methodologies like uncontrolled studies.
• Analysis of experiences with accelerated market access programs.

Main Results:

• Adaptive licensing allows for phased market authorization, initially for specific patient subgroups or indications.
• Subsequent authorization extensions are planned as new data become available.
• The process may incorporate evidence from studies with less rigorous methodologies.

Conclusions:

• Adaptive licensing offers a potential route for earlier patient access to novel therapies.
• Concerns exist regarding the long-term benefit-risk balance and potential for prolonged market presence of drugs with unfavorable profiles.
• The issue of manufacturer liability and patient compensation for adaptively licensed drugs requires careful consideration.